Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom.
The last earnings update was 205 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Midatech Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Midatech Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Midatech Pharma's earnings are expected to grow significantly at over 20% yearly.
Midatech Pharma's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Midatech Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Craig Richard Cook, MBBCH, BSc (Hons), DA, MD, MBA has been Chief Executive Officer and Director of Midatech Pharma Plc since June 1, 2018 and its Chief Operating Officer since January 1, 2014. He was Chief Medical Officer at Midatech Pharma Plc since January 1, 2014. He serves as a Director of 2X1Y Ltd., CareHealth Sarl, SedateUK Ltd, Shawlmist Limited., SpaceCode SA., Swisscare Health Limited., and Winstead Assets Ltd. He served as a Director of Sedation Solutions Limited. Dr. Cook was Head of Research & Development at Midatech Pharma Plc. Dr. Cook joined Midatech in 2014 after leading and concluding the Ippon Capital investment round. He is lead adviser for Ippon Capital SA's life sciences practice. Hehas more than 15 years of international experience in the pharma, biomedical and high technology sectors including roles across a range of therapeutic areas, such as neurology, inflammatory, immunology and endocrine, covering both drug development and medical affairs. He has established and led several healthcare initiatives including SpaceCode Healthcare Technologies, Sedation Solutions and SwissCare Health care provider. Dr. Cook held senior positions at Serono Biotech, Novartis Pharma, Eli Lilly and Johnson & Johnson. He is a qualified physician. Dr. Cook has a B.Sc. in Pharmacology, Diploma in Anaesthesiology and M.B.A. from the London Business School.
Insufficient data for Craig to compare compensation growth.
Insufficient data for Craig to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Midatech Pharma management team is about average.
CFO, Company Secretary & Director
CEO, COO & Director
Head of Corporate Development
Chief Business Officer
Head of Manufacturing
Head of Research & Development
President of Midatech Pharma US Inc
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Midatech Pharma board of directors is about average.
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.